Transcription of Guideline - ESGE
{{id}} {{{paragraph}}}
Example: confidence
Guideline - ESGE
GuidelineManagement of epithelial precancerous conditions and lesions inthe stomach (MAPS II): European Society of GastrointestinalEndoscopy (ESGE), EuropeanHelicobacterand Microbiota StudyGroup (EHMSG), European Society of Pathology (ESP), andSociedade Portuguesa de Endoscopia Digestiva (SPED) guidelineupdate 2019 AuthorsPedro Pimentel-Nunes1,2,3, Diogo Lib nio1,2, Ricardo Marcos-Pinto2,4, Miguel Areia2,5,MarcisLeja6,Gianluca Esposito7, Monica Garrido4, Ilze Kikuste6, Francis Megraud8, Tamara Matysiak-Budnik9, Bruno Annibale7,Jean-Marc Dumonceau10, Rita Barros11,12,Jean-Fran oisFl jou13, F tima Carneiro11,12,14, Jeanin E. van Hooft15,Ernst J. Kuipers16, Mario Dinis-Ribeiro1,2 Institutions1 Gastroenterology Department, Portuguese OncologyInstitute of Porto, Portugal2 Center for Research in Health Technologies andInformation Systems (CINTESIS), Faculty of Medicine,Porto, Portugal3 Surgery and Physiology Department, Faculty ofMedicine of the University of Porto, Porto, Portugal,4 Department of Gastroenterology, Porto UniversityHospital Centre, Instit
1 Patients with chronic atrophic gastritis or intestinal metaplasia are at risk for gastric adenocarcinoma. High quality evidence (100% agree [94% strongly or moderately agree]). STATEMENT 2 Histologically confirmed intestinal metaplasia is the most reliable marker of atrophy in gastric mucosa. High quality evidence (100% agree [100% strongly or
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: